NCT04577313

Brief Summary

The proposed research will conduct the first dose-determination trial to find the optimal number of behavioral counseling sessions (dose) needed to achieve and sustain optimal HIV treatment adherence. The results of this study will determine how much intervention is needed for whom and at what cost to guide health policy and implementation of behavioral interventions designed to improve durable viral suppression.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P50-P75 for not_applicable hiv-infections

Timeline
6mo left

Started Sep 2020

Longer than P75 for not_applicable hiv-infections

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress92%
Sep 2020Nov 2026

Study Start

First participant enrolled

September 1, 2020

Completed
22 days until next milestone

First Submitted

Initial submission to the registry

September 23, 2020

Completed
13 days until next milestone

First Posted

Study publicly available on registry

October 6, 2020

Completed
6.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2026

Last Updated

August 29, 2025

Status Verified

August 1, 2025

Enrollment Period

6.2 years

First QC Date

September 23, 2020

Last Update Submit

August 22, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Change in Antiretroviral Therapy Adherence from Baseline to 12-Months

    Medication adherence defined by percentage of medication doses taken as prescribed

    12-Month

  • Change in HIV Viral Load from Baseline to 12-months

    Blood plasma HIV RNA

    12-months

Study Arms (2)

Continuous Counseling

ACTIVE COMPARATOR

Receives up to 16 weekly behavioral counseling sessions over the phone to achieve optimal medication adherence. Counseling adjusts to patient needs and determines the dose to achieve optimal adherence / HIV suppression, in contrast to the fixed dose condition that does not adjust to patient response.

Behavioral: Behavioral Self-Regulation Adherence Counseling

Fixed Counseling

ACTIVE COMPARATOR

Receives up to five weekly behavioral counseling sessions over the phone focused on improving HIV medication adherence / viral suppression.

Behavioral: Behavioral Self-Regulation Adherence Counseling

Interventions

Telephone-delivered counseling to focus on cognitive-behavioral skills to improve HIV treatment adherence.

Continuous CounselingFixed Counseling

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Confirmed HIV positive
  • Confirmed prescribed antiretroviral therapy
  • Confirmed non-adherent to anti-retroviral therapy

You may not qualify if:

  • Does not have access to a phone
  • Does not have access to the internet

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

University of Connecticut

Storrs, Connecticut, 06269, United States

RECRUITING

University of Connecticut Field Site

Atlanta, Georgia, 30308, United States

RECRUITING

Related Publications (1)

  • Kalichman SC, Kalichman MO, Cherry C, Eaton LA, Cruess D, Schinazi RF. Randomized Factorial Trial of Phone-Delivered Support Counseling and Daily Text Message Reminders for HIV Treatment Adherence. J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):47-54. doi: 10.1097/QAI.0000000000001020.

    PMID: 27105048BACKGROUND

MeSH Terms

Conditions

HIV Infections

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Central Study Contacts

Seth Kalichman, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 23, 2020

First Posted

October 6, 2020

Study Start

September 1, 2020

Primary Completion (Estimated)

November 30, 2026

Study Completion (Estimated)

November 30, 2026

Last Updated

August 29, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Data sets masked for all patient level identifying information.

Locations